FDA trumpeted its support for novel clinical trial designs using master protocols with a review article in the New England Journal of Medicine authored by top drug review officials.
"As the targets for new drugs become more and more precise, there is no alternative but to move forward with these coordinated research efforts," Center for Drug Evaluation and Research Director Janet Woodcock and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?